Clin Mol Hepatol.  2018 Sep;24(3):331-338. 10.3350/cmh.2018.0006.

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease

• Sayari S
• Neishaboori H
• Jameshorani M

• KMID: 2428761
• DOI: http://doi.org/10.3350/cmh.2018.0006

Abstract

BACKGROUND/AIMS
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of patients with NAFLD.
METHODS
In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients were randomized to one of the following treatments for 16 weeks: Group I (n=68), sitagliptin 50 mg daily plus placebo (one capsule per day) or group II (n=70) sitagliptin 50 mg daily plus synbiotic (one capsule per day). Changes in fasting blood glucose (FBS), liver enzymes, lipid profile, and body mass index were compared between the groups.
RESULTS
The mean change in FBS with sitagliptin-placebo from baseline was -10.47±5.77 mg/dL, and that with sitagliptin-synbiotic was -13.52±4.16 mg/dL. There was a significant difference between the groups (P < 0.001). The mean change in cholesterol (Chol) was -8.34±28.83 mg/dL with sitagliptin-placebo and -21.25±15.50 mg/dL with sitagliptinsynbiotic. There was a significant difference between the two groups (P=0.029). The administration of sitagliptin-placebo induced an increase of 6.13±27.04 mg/dL in low density lipoprotein (LDL), whereas sitagliptin-synbiotic induced a decrease of 14.92±15.85 mg/dL in LDL. A significant difference was observed between the two groups (P < 0.001). On the other hand, in the sitagliptin-synbiotic group, there was significant improvement in aspartate aminotransferase (AST) level compared to the sitagliptin-placebo group (P=0.018).
CONCLUSIONS
Sitagliptin-synbiotic produced greater improvement in FBS, AST, Chol, and LDL compared to sitagliptin alone in patients with NAFLD.

Keyword

Non-alcoholic fatty liver disease; Randomized controlled trial; Synbiotic; Sitagliptin

MeSH Terms

Aspartate Aminotransferases
Blood Glucose
Body Mass Index
Cholesterol
Fasting
Hand
Humans
Lipoproteins
Liver
Liver Diseases
Non-alcoholic Fatty Liver Disease*
Sitagliptin Phosphate*
Synbiotics*
Aspartate Aminotransferases
Blood Glucose
Cholesterol
Lipoproteins
Sitagliptin Phosphate